NCT05993338Completed
Pulmonary Artery Pressure in COVID-19 Survivors
Assessment of Pulmonary Artery Pressure in COVID-19 Survivors Using Right Heart Catheterization
Source: ClinicalTrials.gov · Last updated 17 Jun 2024
Brief summary (registry, in English)
Post COVID-19 pulmonary hypertension can develop as a result of lung parenchymal damage and altered pulmonary circulation induced by COVID-19 infection. It has been proposed that this type of PH should be considered a combination between PH of group 3 (due to interstitial fibrosis and alveolar inflammation) and 4 (induced by thrombotic/thromboembolic processes, endothelial injury, or, at least, hypoxic vasoconstriction). Right heart catheterization (RHC) is the gold standard for assessing pulmonary hemodynamics and is mandatory for confirming the diagnosis of pulmonary hypertension (PH), assessing the severity of hemodynamic impairment, and performing vasoreactivity testing in selected patients
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 13 Aug 2023
- Start date
- 1 Apr 2022
- Primary completion date
- 1 Apr 2023
- Lead sponsor
- Mansoura University Hospital
- NCT number
- NCT05993338
What you commit to
- Study type: Interventional
- Participants enrolled: 15
- From 1 Apr 2022 to the primary completion date, 1 Apr 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Previous diseases that could explain the existence of PH e.g. cardiovascular, pulmonary diseases or history of pulmonary thromboembolism.
- Infection at the insertion site.
Lab values
- Coagulopathy (INR \>1.5), thrombocytopenia (platelet count \<50,000/microL).
Other
- Hemodynamic instability.
- Absolute contraindications to RHC placement include:
- The presence of a right ventricular assist device.
- Insertion during cardiopulmonary bypass.
- Lack of consent.
- Relative contraindications to RHC placement include:
- Electrolyte disturbances.
- Severe acid-base disturbances.
Who the study is looking for
- COVID-19 survivors from a moderate/severe COVID-19 pulmonary infection according to WHO COVID-19 clinical severity classification , ≥ 18 years, with residual symptoms and signs suggestive of pulmonary hypertension and not explained by other condition.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine, Mansoura University Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.